Myeloperoxidase deficiency is a genetic condition that affects how certain white blood cells kill germs. Many people with myeloperoxidase deficiency have no noticeable symptoms, but some get more frequent mouth, skin, or genital yeast infections. It is lifelong and often found in adulthood during routine blood tests, though it can be recognized in childhood. Most people live a normal lifespan, and serious infections are uncommon but can occur in those with diabetes or weakened immunity. Treatment focuses on managing infections with antifungals or antibiotics, and talking with your healthcare provider can bring clarity and reassurance.
Overview
Myeloperoxidase deficiencySymptoms
Myeloperoxidase deficiency often has no clear signs. Some people have frequent mouth, skin, or genital yeast infections (Candida) or recurrent bacterial infections, especially if living with diabetes. It’s sometimes found incidentally on routine blood tests.
Outlook and prognosis
Most people with myeloperoxidase deficiency stay well and lead full lives, with either no symptoms or only mild, repeat mouth or skin infections. Serious infections are uncommon but can occur, especially with diabetes or immune‑suppressing medicines. Regular check-ins and prompt treatment keep risks low.
Causes and risk factors
Myeloperoxidase deficiency usually results from inherited MPO gene variants (autosomal recessive). Risk is higher with family history or parents who are related. Severity is often shaped by diabetes, immunosuppression, chemotherapy, or blood cancers, which raise infection susceptibility.
Genetic influences
Genetics play a central role in myeloperoxidase deficiency, which is usually inherited in an autosomal recessive pattern. Many people carry one altered MPO gene without symptoms. Variations can influence enzyme activity and infection risk, but severity ranges widely.
Diagnosis
Diagnosis of Myeloperoxidase deficiency usually starts with neutrophil function testing, such as myeloperoxidase staining or flow cytometry. Genetic diagnosis of Myeloperoxidase deficiency uses MPO gene testing. Clinical features, like recurrent fungal infections, can support the diagnosis.
Treatment and drugs
Treatment for myeloperoxidase deficiency focuses on preventing and managing infections. Doctors often recommend good oral and skin care, prompt treatment of bacterial or fungal infections, and, in select cases, preventive antifungal or antibiotic medicines. People with frequent infections may see an immunology or infectious-disease specialist for tailored plans.
Symptoms
Many people with myeloperoxidase (MPO) deficiency have no obvious health problems in daily life and may never realize they have it. When present, early features of Myeloperoxidase deficiency usually show up as common yeast infections on the skin, in the mouth, or in the genital area. Features vary from person to person and can change over time. People with diabetes or weakened immunity may notice more frequent or stubborn infections.
Many people feel completely well with no day-to-day issues, and MPO deficiency is found only on a lab test. No treatment is needed when infections are not a problem.
White, cottage cheese-like patches on the tongue or cheeks can be sore or make food taste off. It may follow antibiotics or steroid inhalers and can come back.
Itching, thick white discharge, and burning may recur. Symptoms may be more frequent in MPO deficiency, especially with high blood sugar.
Red, itchy, sometimes cracked skin in warm, moist areas such as under the breasts or in the groin can signal yeast overgrowth. It may improve with keeping the area dry and antifungal creams.
How people usually first notice Myeloperoxidase deficiency?
Many people learn about myeloperoxidase (MPO) deficiency only after a routine blood test flags “abnormal neutrophil function” during workup for repeated mouth or skin infections, sinus issues, or slow-to-heal sores. In newborns and children, there usually aren’t obvious signs at birth, but doctors may suspect it if a child has frequent superficial infections or if specialized labs note absent MPO staining in neutrophils while other counts look normal. Adults are often diagnosed incidentally through specialized testing after recurrent Candida (yeast) infections or when an immune evaluation is done for stubborn, mild infections—these patterns are the first signs of MPO deficiency and how it’s first noticed.
Types of Myeloperoxidase deficiency
Myeloperoxidase deficiency is a genetic condition, and there are recognized clinical variants that differ mainly by how much enzyme activity remains and when it shows up. These variants can affect how often people get certain infections, how severe those infections are, and whether symptoms are noticed at all. Many live for years without knowing they have it, while others have frequent mouth or skin infections that keep coming back. Not everyone will experience every type.
Complete deficiency
Enzyme activity is nearly absent, often due to changes in both copies of the MPO gene. People may have more frequent or stubborn Candida or bacterial infections, especially in the mouth, skin, or genitals. Some have no clear symptoms until testing is done.
Partial deficiency
Some enzyme function remains, and infections tend to be milder or less frequent. Many are identified incidentally during blood tests, with few day-to-day problems. The balance of symptoms can shift over time.
Classic (congenital) form
Genetic from birth, with stable findings on lab tests throughout life. Symptoms, if present, usually start in childhood or early adulthood as recurrent minor infections. People may notice slower healing from small cuts or gum irritation.
Acquired/transient form
Reduced MPO activity develops later, for example during certain illnesses or with some medications, and can improve once the trigger resolves. Infections may cluster during the low-activity period and then ease. This helps explain why types of myeloperoxidase deficiency can vary over time.
What genetics can tell you about symptoms
People with certain MPO gene changes may have frequent mouth ulcers, gum inflammation, or stubborn skin and nail infections, especially with Candida yeast, because white blood cells kill germs less effectively. Rarely, specific MPO variants link to more severe bacterial infections or to inflammation flares.
Causes and risk factors
Most causes of Myeloperoxidase deficiency are genetic and involve changes in the MPO gene inherited from both parents. In a few people, low MPO activity can also show up later with certain blood disorders or severe illness. Genes set the stage, but environment and lifestyle often decide how the story unfolds. Risk of infections is higher with poorly controlled diabetes and with frequent exposure to germs like yeast. Having two carrier parents raises a child’s risk, and carriers usually do not have symptoms.
Environmental and biological risk factors
Myeloperoxidase deficiency can be present from birth or, less often, appear later due to other health conditions or exposures. Some risks are carried inside the body, others come from the world around us. Below are biological and environmental risk factors for Myeloperoxidase deficiency linked to lower myeloperoxidase levels or activity.
High blood sugar can blunt this enzyme in certain white blood cells, leading to lower myeloperoxidase activity. This makes acquired MPO deficiency more likely in some people with diabetes.
Waste buildup in the blood (uremia) can weaken white blood cell function and suppress this enzyme. People with chronic kidney disease or on dialysis sometimes show lower MPO levels.
Diseases that change how white blood cells mature, including some blood cancers, can reduce how much myeloperoxidase these cells produce. This can result in laboratory evidence of MPO deficiency.
Treatments that temporarily suppress bone marrow can lower enzyme content in newly formed white blood cells. MPO deficiency may be seen during therapy and often improves as recovery occurs.
Genetic risk factors
The genetic causes of Myeloperoxidase deficiency involve changes in the MPO gene that reduce the myeloperoxidase enzyme in white blood cells. It is usually inherited in a recessive pattern, where two changed copies are needed to be affected. Carrying a genetic change doesn’t guarantee symptoms will appear. Severity can vary by the exact MPO variants, and many people with Myeloperoxidase deficiency have no symptoms or only mild infections.
MPO gene variants: Changes in the MPO gene reduce or eliminate the myeloperoxidase enzyme in white blood cells. Different variants can cause partial or complete Myeloperoxidase deficiency. Genetic testing can identify the specific change.
Recessive inheritance: You typically need two changed copies—one from each parent—to have Myeloperoxidase deficiency. Parents are usually healthy carriers. Each pregnancy has a 25% chance of an affected child.
Carrier state: People with one changed MPO copy are carriers and usually have no health problems. Lab tests may show lower enzyme activity without symptoms. Carriers can pass the variant to children.
Two different changes: Having two different MPO variants, one on each copy, can also lead to the condition. The mix of variants can influence how much enzyme is left. This partly explains why Myeloperoxidase deficiency looks different from person to person.
Variable symptoms: Even with the same MPO variants, features can range from none to occasional infections. Genetics alone does not fully predict who will have symptoms. Doctors may use both genetic and blood enzyme tests to clarify risk.
Family history: Having siblings or relatives with the condition raises the chance you carry the same MPO variant. In families with multiple affected members, testing can clarify who is at risk. Genetic counseling can help with planning.
Shared ancestry: Certain MPO changes recur in specific ancestries or communities due to shared roots. This can make the condition more common in those groups. A clinician may choose targeted testing based on family origins.
Parental relatedness: When parents are related by blood, the chance of both carrying the same MPO variant is higher. This raises the likelihood of children having Myeloperoxidase deficiency. The degree of relatedness affects risk.
Lifestyle risk factors
Lifestyle habits do not cause Myeloperoxidase deficiency, but they can influence infection risk, symptom burden, and complications. Focusing on daily routines that support barrier health, oral and skin microbiomes, sleep, and metabolic control can lower the chance of fungal and some bacterial infections. This overview highlights how lifestyle affects Myeloperoxidase deficiency and pinpoints lifestyle risk factors for Myeloperoxidase deficiency. Choose the elements most relevant to your day-to-day life and medical comorbidities such as diabetes.
Frequent sugary foods can promote oral and genital Candida overgrowth. With MPO-deficient neutrophils, yeasts face less oxidative killing and can take hold more easily.
Stable blood sugars from fiber-rich, low-glycemic meals reduce infection-prone high-glucose environments. In MPO deficiency with diabetes, tighter control can lower thrush and skin infection risk.
Regular moderate exercise improves insulin sensitivity and mucosal immune tone. For MPO deficiency, this may indirectly reduce fungal infections linked to hyperglycemia and deconditioning.
Twice-daily brushing, flossing, and antimicrobial rinses reduce biofilm and Candida load. In MPO deficiency, this can curb recurrent oral thrush and periodontal flares.
Risk prevention
You can’t prevent being born with this enzyme shortage, but you can lower infection risks with a few steady habits and timely care. Prevention is about lowering risk, not eliminating it completely. Most people with myeloperoxidase deficiency never get serious infections, but higher risk can show up if you also live with diabetes or have frequent antibiotic use. Knowing early symptoms of myeloperoxidase deficiency—like repeated oral thrush, stubborn skin infections, or slow-healing sores—helps you act quickly.
Keep routine vaccines current to prevent respiratory and other infections. Ask about flu, COVID-19, and pneumonia shots based on your age and health.
Wash hands often, cook and store food safely, and avoid sharing razors or toothbrushes. This matters for people with myeloperoxidase deficiency because certain germs are harder for their white cells to clear.
Brush and floss every day, clean dentures well, and address dry mouth to reduce thrush and gum infections. Regular dental check-ups help catch problems early.
Keep skin moisturized, promptly clean and cover cuts, and change out of damp socks or clothes. People with myeloperoxidase deficiency and diabetes should inspect feet daily.
Transmission
Myeloperoxidase deficiency is not contagious; it cannot be caught through coughing, touch, sex, or shared items. It is usually inherited in an autosomal recessive way, meaning both parents typically carry one nonworking copy of the MPO gene without symptoms; with each pregnancy, there is a 1 in 4 (25%) chance the child will have the condition, a 1 in 2 (50%) chance the child will be a carrier, and a 1 in 4 (25%) chance of having neither. New changes in the MPO gene can occur but seem uncommon. If you’re wondering about the genetic transmission of Myeloperoxidase deficiency or how Myeloperoxidase deficiency is inherited, a genetics professional can help clarify risks for your family.
When to test your genes
Consider testing if you’ve had repeated bacterial or fungal infections, stubborn mouth or skin infections, or slow wound healing, especially with a family history of immune issues. Genetic testing also helps if your blood tests suggest neutrophil problems or before starting immune‑suppressing treatments. Results can guide infection prevention, vaccines, and tailored monitoring.
Diagnosis
Myeloperoxidase deficiency is usually identified through lab testing rather than obvious outward signs, since many people have few or no symptoms. When infections happen, they’re often mild and related to yeast such as Candida, which can prompt a closer look at white blood cell function. Doctors confirm the condition by showing that a specific enzyme inside certain white cells is missing or very low, then may verify the exact genetic change. Many people feel relief just knowing what’s really going on.
Your provider asks about repeated mouth or skin infections, thrush, or slow-healing sores, especially if you live with diabetes. Patterns over time help decide which tests to order.
The exam looks for signs of fungal or bacterial infection on the skin, nails, and mucous membranes. Findings help target the most useful lab tests.
A complete blood count with differential is often normal in myeloperoxidase deficiency. Results help exclude other white blood cell problems.
Cytochemical peroxidase staining on a blood smear shows reduced or absent MPO activity in neutrophils. This is a classic laboratory clue that points toward the diagnosis.
Stages of Myeloperoxidase deficiency
Myeloperoxidase deficiency does not have defined progression stages. This enzyme change is usually present from birth and tends to stay stable over time, and any infections that occur are episodic rather than part of a stepwise decline—early symptoms of myeloperoxidase deficiency can be subtle or even absent. Diagnosis is usually made with specialized blood tests that look at how white blood cells handle germs and with enzyme staining; sometimes a genetic test is offered to confirm the cause or discuss family implications. Many people feel reassured knowing what their tests can—and can’t—show.
Outlook and prognosis
Looking at the long-term picture can be helpful. For most people with Myeloperoxidase deficiency, day-to-day life is largely unaffected, and life expectancy is normal. Many people discover the condition only after routine blood tests; others find out because they have more frequent mouth or skin infections, slow-healing gum issues, or stubborn fungal infections like thrush or athlete’s foot. Severe, life‑threatening infections are uncommon, but the risk can rise if someone also has diabetes, is on immune‑suppressing medicines, or is very elderly.
Prognosis refers to how a condition tends to change or stabilize over time. In Myeloperoxidase deficiency, the immune gap is usually stable across the lifespan—it doesn’t typically “worsen” with time—and many living with MPO deficiency never need specific treatment. When infections do occur, they’re often mild to moderate and respond to standard care, though they may take a bit longer to clear. Rare complications include deep‑seated fungal infections; these are more likely when there are other immune stresses, so clinicians watch higher‑risk groups more closely. Early symptoms of Myeloperoxidase deficiency that warrant attention include repeated oral thrush, recurrent sinus infections, or unusually slow healing after dental work.
The outlook is not the same for everyone, but with routine preventive care—good dental hygiene, skin care, timely vaccines, and prompt treatment of infections—most people maintain normal routines. Mortality related directly to Myeloperoxidase deficiency is rare; deaths, when reported, usually involve additional risk factors and serious fungal infection. Talk with your doctor about what your personal outlook might look like.
Long-term effects
Many people live their whole lives without infections, while others deal with repeat mouth or skin issues that come and go. Long-term effects vary widely, and most people have a typical life span. Myeloperoxidase deficiency is often found on routine blood testing rather than through symptoms, and early symptoms of myeloperoxidase deficiency may be subtle or absent. A small group—especially those living with diabetes—may face more persistent candida or bacterial infections over time.
Many people with myeloperoxidase deficiency remain healthy with no ongoing infections. The condition is often discovered incidentally on blood or enzyme testing.
Mouth, genital, or skin yeast infections may recur over months or years. These are usually localized but can be stubborn.
When diabetes is present in myeloperoxidase deficiency, infections tend to be more frequent and harder to clear. Severe or widespread Candida infections have been reported in this group.
Some with myeloperoxidase deficiency experience more skin, urinary, or wound infections. Serious bacterial infections are uncommon.
How is it to live with Myeloperoxidase deficiency?
Living with myeloperoxidase (MPO) deficiency often feels uneventful day to day because most people have no symptoms and lead typical lives; the immune system has many backups, so routine colds and cuts usually heal normally. A minority may notice more mouth or skin infections, slower recovery from fungal issues like thrush, or tougher courses when diabetes is present, which can mean extra check-ins with a clinician and prompt care for wounds or fevers. Family members and close contacts rarely need to change their routines, though they may help by encouraging timely medical attention for infections and supporting everyday prevention like good oral care and handwashing. For many, the main “work” is simply awareness: knowing to seek care earlier for persistent infections while continuing usual activities, school, work, and exercise.
Treatment and drugs
Treatment for myeloperoxidase (MPO) deficiency depends on how it shows up in daily life. Most people with MPO deficiency never need treatment because they feel well and have typical immune function; care usually focuses on routine health habits, dental care, and prompt attention to infections. If infections occur, doctors treat them as usual with targeted antibiotics or antifungals, and they may suggest vaccines on schedule to lower risk from preventable illnesses. People with diabetes or other immune-weakening conditions may need closer follow-up because MPO deficiency can make certain fungal infections more likely; your doctor may recommend earlier testing or more aggressive therapy if symptoms suggest a deep infection. Although living with Myeloperoxidase deficiency can feel overwhelming at first, most find that regular checkups, good wound care, and timely treatment of infections are enough to stay well.
Non-drug treatment
Most people with myeloperoxidase deficiency stay well, but a few have more frequent or stubborn yeast or skin infections that affect daily comfort. Non-drug treatments often lay the foundation for staying healthy by lowering infection risk and catching issues early. Practical steps at home and in clinics can make a real difference alongside any needed prescriptions. Knowing the early symptoms of infection in myeloperoxidase deficiency—such as new mouth sores, thrush, or skin redness—helps you seek care sooner.
Wash hands regularly with soap and water, especially after the bathroom, before eating, and after touching animals. Alcohol gel is a useful backup when water isn’t available. Keep nails short to reduce trapped germs.
Clean cuts right away with mild soap and water, then cover with a clean bandage. Change dressings daily and watch for spreading redness or pus. Seek care quickly if a wound isn’t improving within a day or two.
Brush twice daily and floss to keep gums healthy and reduce thrush risk. Rinse and dry dentures nightly; consider removing them during sleep. Schedule routine dental checkups to catch early mouth changes.
Moisturize dry, cracked skin to protect the barrier against germs. Inspect feet and skin folds daily for redness, peeling, or moist areas that can invite yeast. Choose breathable socks and change out of damp clothes promptly.
Your genes may have an impact on how drugs work for you
Genes can change how your body processes certain infection‑fighting drugs, so doses or choices may need adjusting if you have myeloperoxidase deficiency. Pharmacogenetic testing and careful monitoring help clinicians pick safer, effective options and avoid medicines that could worsen infections.
Pharmacological treatments
Most people with myeloperoxidase deficiency never need daily medicine, and treatment focuses on infections if and when they arise. Sometimes medicines are taken short-term (acute treatment), while others are used long-term (maintenance therapy). When fungal infections like oral thrush or recurrent vaginal yeast occur, antifungals are the mainstay. Severe or invasive infections are treated in hospital with stronger antifungals; antibiotics are used for routine bacterial infections as usual.
Many without early symptoms of myeloperoxidase deficiency do not need preventive medicine. Treatment is started only if infections develop. Your care team may simply monitor and step in promptly if problems arise.
Clotrimazole, miconazole, or nystatin can treat oral, skin, or vaginal yeast infections. These are applied directly where needed and usually work within days. They have few body-wide side effects.
Fluconazole or itraconazole can help with recurrent mucocutaneous Candida infections. These pills may interact with other medications and can affect the liver, so doctors may check labs. Doses and duration depend on the site and severity of infection.
Caspofungin, micafungin, or anidulafungin are IV medicines for suspected or proven invasive candidiasis. They are often started in the hospital when someone is ill or cannot take pills. Liver tests are sometimes monitored during treatment.
Genetic influences
Most cases of myeloperoxidase deficiency are inherited due to changes in a single gene called MPO. It usually follows a recessive pattern: you typically need two changed versions—one from each parent—for the enzyme to be low or missing. A “carrier” means you hold the gene change but may not show symptoms. When both parents are carriers, each pregnancy has a 25% chance of a child with myeloperoxidase deficiency, a 50% chance the child will be a carrier, and a 25% chance of neither. People with the same MPO gene changes can be affected differently; many have no infections at all, while risk may rise when other health conditions such as diabetes are present. If you’re wondering “is myeloperoxidase deficiency inherited,” genetic counseling and, in some cases, genetic testing for myeloperoxidase deficiency can help clarify your family’s risk.
Is Myeloperoxidase deficiency genetic?
Genetics play a central role in myeloperoxidase deficiency, which is usually inherited in an autosomal recessive pattern. Many people carry one altered MPO gene without symptoms. Variations can influence enzyme activity and infection risk, but severity ranges widely.
Pharmacogenetics—how genetics influence drug effects
Although Myeloperoxidase deficiency is inherited, it rarely calls for changing standard medicines based solely on the MPO gene; care mainly focuses on preventing and treating infections promptly. Genes can influence how quickly you break down some antifungal drugs, such as voriconazole, which can change the dose that works best. Because of this, some clinicians may use pharmacogenetic testing to guide voriconazole dosing or check drug levels in the blood if treatment isn’t working as expected or side effects show up. There is no approved enzyme replacement or gene therapy for Myeloperoxidase deficiency, so treatment is tailored to the infection, your overall health, and possible drug interactions. Your MPO result itself doesn’t change how your liver processes most medicines, so dose adjustments are usually driven by the specific drug rather than the condition. If you live with diabetes or have frequent Candida infections, your team may be more proactive with antifungal treatment and prevention. Age, liver function, and other medicines you take also play a big role in how antifungals are chosen and dosed.
Interactions with other conditions
When Myeloperoxidase deficiency occurs alongside other illnesses that affect immune function, infections can happen more often and may be harder to clear. Doctors call it a “comorbidity” when two conditions occur together. Diabetes is the most common example; high blood sugar can blunt white blood cell activity, so people with Myeloperoxidase deficiency and diabetes may see more yeast infections (thrush), skin infections, or urinary tract infections. Because early symptoms of Myeloperoxidase deficiency are often absent, the first clues may surface when another condition—like poorly controlled diabetes, HIV, or treatment with steroids or chemotherapy—triggers recurrent infections. Myeloperoxidase deficiency can also compound risk if you already have low neutrophil counts or another immune disorder, as these issues stack to reduce the body’s ability to kill certain fungi and bacteria. Interactions can look very different from person to person, so coordinated care across your specialists helps tailor prevention and treatment.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns of frequent mouth sores, stubborn gum infections, or skin boils that took longer to clear in some relatives, even when others recovered quickly from the same colds or cuts. Long before lab tests, people with Myeloperoxidase deficiency often lived mostly normal lives, but a few faced repeated yeast infections or slow-healing wounds that puzzled local doctors.
First described in the medical literature as a lack of a key white blood cell enzyme in the mid‑20th century, Myeloperoxidase deficiency gradually moved from a laboratory curiosity to a recognized immune variation seen in many countries. Early reports focused on striking cases with serious infections. Later, as routine blood tests improved, clinicians realized many people carried this deficiency without obvious illness, which explained why the condition seemed rare at first and more common once screening broadened.
From early theories to modern research, the story of Myeloperoxidase deficiency has been shaped by careful observation at the microscope. In the 1950s and 1960s, staining techniques showed some neutrophils—our main infection‑fighting cells—were missing their usual green‑tinged enzyme activity. Over time, descriptions became more precise, separating complete enzyme loss from milder, partial forms. This helped explain why some people had frequent fungal infections while others had no symptoms at all.
Advances in genetics in the late 20th and early 21st centuries confirmed that changes in the MPO gene can disrupt or reduce the enzyme’s function. Researchers also linked certain patterns—such as diabetes or heavy antibiotic use—to higher chances of noticeable infections in people with Myeloperoxidase deficiency. Despite evolving definitions, the historical record shows a consistent theme: most people identified through screening feel well, while a smaller group experiences recurrent infections that benefit from closer follow‑up.
In recent decades, awareness has grown as automated blood analyzers occasionally flag absent myeloperoxidase activity during routine checks. That shift, from finding Myeloperoxidase deficiency only after serious illness to often spotting it incidentally, has reassured many and reframed care toward prevention and monitoring. Today’s understanding blends those first microscopic clues with genetic insights, giving a clearer picture of who may be affected and when extra support is helpful.
Looking back helps explain why guidance now emphasizes context: the same laboratory finding can have very different day‑to‑day impacts. This perspective—built over decades—guides current care, from recognizing early symptoms of Myeloperoxidase deficiency when they appear to avoiding unnecessary alarm when they do not.